April - June 2010

June 29, 2010		AMAG Pharmaceuticals and Takeda Announce Acceptance of Submission of Feraheme® Marketing Authorization Application to the European Medicines Agency and Initiation of Global Registrational Program for Feraheme for the Treatment of Iron Deficiency Anemia
June 28, 2010		Takeda Appoints Two Executive-level Personnel from Outside the Company
June 28, 2010		Takeda Announces Appointment of New Executive and Corporate Officer
June 25, 2010		Takeda Announces Appointment of New Corporate Officers
June 25, 2010		Notice Concerning Stock Options (Stock Acquisition Rights) for Members of the Board of Directors
June 23, 2010		Takeda to Expand Presence in Asia with Operations in South Korea
June 22, 2010		ACTOplus met® XR (pioglitazone HCl and metformin HCl extended-release)Now Available in Pharmacies Nationwide
June 21, 2010		AFFYMAX AND TAKEDA ANNOUNCE PHASE 3 TRIALS MEET PRIMARY ENDPOINTS FOR INVESTIGATIONAL DRUG, HEMATIDE™/PEGINESATIDE, TO TREAT ANEMIA IN CHRONIC RENAL FAILURE WITH SOME DIFFERENCES NOTED IN SECONDARY ANALYSES
June 18, 2010		Approval of Additional Indications for Helicobacter pylori Eradication by Concomitant Therapy with Proton Pump Inhibitors
June 17, 2010		CanBas and Takeda to Terminate Collaboration for CBP501 for the Treatment of Cancer
June 15, 2010		Launches of "NESINA®" for treatment of type 2 diabetes, "UNISIA®" for treatment of hypertension and "Vectibix®", anti-cancer agent, in Japan
June 2, 2010		Takeda Achieves Zero Emissions at its Plants in Japan
May 21, 2010		Takeda Announces Change in Management with the Establishment of New Organization
May 12, 2010		2010-2012 Mid-Range Plan Transformation for a New Takeda
May 10, 2010		Takeda to Co-promote VELCADE® (bortezomib) for Injection in Japan
May 7, 2010		Announcement regarding Establishment of Sponsored ADR Program
April 28, 2010		Takeda Provides Update on Patent Litigation for ACTOS® (pioglitazone HCl) and ACTOplus met® (pioglitazone HCl and metformin HCl) in the U.S.
April 28, 2010		Takeda Submits New Drug Application for Azilsartan Medoxomil in the U.S., an Investigational Compound for the Treatment of Hypertension
April 16, 2010		New Drug Applications Approval for Five New Products in Japan
April 13, 2010		Takeda's Annual Report 2009 and CSR Data Book 2009 receive third prize in Sustainability Reporting Award
April 8, 2010		Seattle Genetics, Takeda and Millennium Announce Initiation of Phase III AETHERA Trial of Brentuximab Vedotin (SGN-35) for Post-Transplant Hodgkin Lymphoma
April 1, 2010		AMAG Pharmaceuticals and Takeda Pharmaceutical Company Announce Strategic Collaboration for Feraheme® in All Therapeutic Indications in Select Ex-US Territories, Including Europe
April 1, 2010		About Agreement Reached to Co-market R113675 (Galantamine Hydrobromide), a Treatment for Alzheimer's Disease